Halozyme Therapeutics (HALO) Net Cash Flow (QoQ) (2010 - 2026)
Halozyme Therapeutics (HALO) Net Cash Flow (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - |
| 3 | Akari Therapeutics | 973.81 Bn | 973.81 Bn | - |
| 4 | BeOne Medicines | 471.45 Bn | 466.66 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.00 Bn | 114.75 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.99 Bn | 61.23 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - |
| 8 | Argenx Se | 55.86 Bn | 50.67 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn |
| 10 | Halozyme Therapeutics | 9.66 Bn | 9.35 Bn | 297.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 161.99% |
| Dec 31, 2025 | -179.16% |
| Sep 30, 2025 | 412.58% |
| Jun 30, 2025 | -289.27% |
| Mar 31, 2025 | 257.22% |
| Dec 31, 2024 | -14.67% |
| Sep 30, 2024 | -244.36% |
| Jun 30, 2024 | -49.77% |
| Mar 31, 2024 | 129.68% |
| Dec 31, 2023 | -393.73% |
| Sep 30, 2023 | -57.31% |
| Jun 30, 2023 | 190.18% |
| Mar 31, 2023 | -258.34% |
| Dec 31, 2022 | 54.79% |
| Sep 30, 2022 | 309.00% |
| Jun 30, 2022 | -2,943.33% |
| Mar 31, 2022 | 99.76% |
| Dec 31, 2021 | -934.05% |
| Sep 30, 2021 | 185.20% |
| Jun 30, 2021 | -114.92% |